TG Therapeutics, Inc. (NASDAQ: TGTX) announced the initiation of a Phase 2 clinical trial evaluating Briumvi (ublituximab-xiiy) in adults with ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE